Internal Med Medical News about Lupus-Like Syndrome

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lupus-Like Syndrome Attributable to Anti--Tumor Necrosis Factor {alpha} Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
Mayo Clinic Proceedings, 11/05/09

Wetter DA et al. – Compared with previous studies, cutaneous findings were less frequent and arthritis was more frequent in our cohort of patients. Some patients were able to tolerate an alternative TNF–[alpha] inhibitor without recurrence of lupus–like syndrome.

<< Previous
A correspondence analysis revealed frailty deficits aggregate and...

Next >>
Handling uncertainty in economic evaluations of patient level...